Otilimab Failure Is A Blow For GSK’s Pipeline, With More Tests To Come

Arthritis Drug Was Blockbuster Candidate

 
• By Andrew McConaghie

GSK is abandoning one of its new drug prospects after it failed in hard-to-treat rheumatoid arthritis patients at Phase III, raising the stakes for more key readouts due shortly.

GSK Stevenage
GSK is aiming to generate around $23bn in revenues from new products, but has had mixed results so far this year. • Source: GSK

GSK’s late-stage pipeline has been dealt a blow by the failure of its rheumatoid arthritis candidate, otilimab, in a Phase III program.

The company has revealed that otilimab, a novel monoclonal antibody treatment for rheumatoid arthritis (RA), met its primary endpoint in...

More from Clinical Trials

More from R&D